Sana Biotechnology Announces Positive Clinical Results From Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression
Sana生物技术宣布无免疫抑制的1型糖尿病胰岛电芯移植研究获得积极临床结果
Sana Biotechnology released what it assessed as positive data from a study of its in-development treatment for type 1 diabetes. The company said it transplanted its treatment, UP421, an allogeneic primary islet cell therapy engineered with its hypoimmune technology, into a patient with type 1 diabetes without the use of any immunosuppression. The study identified no safety issues, and the hypoimmune-modified islet cells evaded immune responses.
Sana生物技术发布了其对正在开发的1型糖尿病治疗方案的积极数据。该公司表示，它将其治疗方案UP421（使用其生物技术设计的异体原发性电芯细胞治疗）移植到一名没有使用任何免疫抑制剂的1型糖尿病患者体内。研究未发现安全问题，经过生物技术修饰的电芯细胞成功躲避了免疫反应。
